Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Srdan Verstovsek, Constantine S. Tam, Martha Wadleigh, Lubomir Sokol, Catherine C. Smith, Lynne A. Bui, Chunyan Song, Douglas O. Clary, Patrycja Olszynski, Jorge Cortes, Hagop Kantarjian, Neil P. Shah

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)316-322
Number of pages7
JournalLeukemia Research
Volume38
Issue number3
DOIs
StatePublished - Mar 1 2014
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Peripheral Nervous System Diseases
Half-Life
Therapeutics

Keywords

  • Inhibitor
  • JAK2
  • Mutation
  • Myelofibrosis
  • XL019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Verstovsek, S., Tam, C. S., Wadleigh, M., Sokol, L., Smith, C. C., Bui, L. A., ... Shah, N. P. (2014). Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research, 38(3), 316-322. https://doi.org/10.1016/j.leukres.2013.12.006

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. / Verstovsek, Srdan; Tam, Constantine S.; Wadleigh, Martha; Sokol, Lubomir; Smith, Catherine C.; Bui, Lynne A.; Song, Chunyan; Clary, Douglas O.; Olszynski, Patrycja; Cortes, Jorge; Kantarjian, Hagop; Shah, Neil P.

In: Leukemia Research, Vol. 38, No. 3, 01.03.2014, p. 316-322.

Research output: Contribution to journalArticle

Verstovsek, S, Tam, CS, Wadleigh, M, Sokol, L, Smith, CC, Bui, LA, Song, C, Clary, DO, Olszynski, P, Cortes, J, Kantarjian, H & Shah, NP 2014, 'Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor', Leukemia Research, vol. 38, no. 3, pp. 316-322. https://doi.org/10.1016/j.leukres.2013.12.006
Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research. 2014 Mar 1;38(3):316-322. https://doi.org/10.1016/j.leukres.2013.12.006
@article{081c3e9b0e144bc08c92d802137021cd,
title = "Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor",
abstract = "This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300. mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50{\%}, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21. h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10{\%}) patients.",
keywords = "Inhibitor, JAK2, Mutation, Myelofibrosis, XL019",
author = "Srdan Verstovsek and Tam, {Constantine S.} and Martha Wadleigh and Lubomir Sokol and Smith, {Catherine C.} and Bui, {Lynne A.} and Chunyan Song and Clary, {Douglas O.} and Patrycja Olszynski and Jorge Cortes and Hagop Kantarjian and Shah, {Neil P.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.leukres.2013.12.006",
language = "English (US)",
volume = "38",
pages = "316--322",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

AU - Verstovsek, Srdan

AU - Tam, Constantine S.

AU - Wadleigh, Martha

AU - Sokol, Lubomir

AU - Smith, Catherine C.

AU - Bui, Lynne A.

AU - Song, Chunyan

AU - Clary, Douglas O.

AU - Olszynski, Patrycja

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Shah, Neil P.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300. mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21. h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.

AB - This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300. mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21. h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.

KW - Inhibitor

KW - JAK2

KW - Mutation

KW - Myelofibrosis

KW - XL019

UR - http://www.scopus.com/inward/record.url?scp=84894253077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894253077&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.12.006

DO - 10.1016/j.leukres.2013.12.006

M3 - Article

C2 - 24374145

AN - SCOPUS:84894253077

VL - 38

SP - 316

EP - 322

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -